An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23™ (MSD Aventis Pasteur) in Elderly Population.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,198
- 试验地点
- 6
- 主要终点
- Response rate to 11 vaccine serotypes
研究概览
简要总结
Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis. Elderly subjects are especially vulnerable to these infections, and the diseases can result in death. The currently available licensed Streptococcus pneumoniae vaccine is recommended for prevention of pneumococcal diseases in individuals over the age of 65. However, the antibody level elicited by this vaccine, is not always satisfactory in elderly people. To overcome the problem, GlaxoSmithKline Biologicals is currently developing candidate vaccines that are hoped to work better than the currently available vaccines. As a first step in this development, the present study is being conducted in order to evaluate the immune response to the currently marketed vaccine.
详细描述
Since influenza vaccination is recommended in the age range of the study population, Fluarix™ (GlaxoSmithKline Biologicals) vaccine will be offered free of charge for the study period (3 consecutive years), to be used by Investigators according to national vaccination schedule/practice.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Response rate to 11 vaccine serotypes
时间窗: One month post vaccination
次要结局
- Anti-polysaccharide total IgG ELISA for 11 vaccine pneumococcal serotypes(At all time points)
- Opsonophagocytic activity against 11 vaccine pneumococcal serotypes in a subset of subjects(At Day 0 and Day 30.)
- The rank of subjects from "poorest responder" to "best responder" based on the number of serotypes each subject responds to(One month post vaccination)
- Persistence of the immune response in a subset of subjects.(Until Month 36.)
- Opsonophagocytic activity response in a subset of subjects.(At Day 30)
- Occurrence of serious adverse events (SAE).(Up to 1 month after vaccination.)
- Occurrence of study related SAEs.(Throughout the study period.)